ALZpath Inks Licensing Deal with Roche for pTau217 Antibody in Alzheimer's Blood Test

Tuesday, June 11, 2024

ALZpath, a leading developer of innovative diagnostic tools and solutions for Alzheimer's disease and related dementias, has announced a strategic license agreement with Roche.

This agreement permits Roche to utilize ALZpath's pTau217 antibody for developing and commercializing a blood test for Alzheimer's disease, integrated into the Roche Elecsys® platform.

The FDA recently granted Breakthrough Device designation to the Roche pTau217 test, which will be part of a collaboration between Roche and Eli Lilly.

The pTau217 antibody is a significant biomarker for detecting Alzheimer's disease in blood, offering accuracy and reliability akin to more invasive methods such as PET imaging or CSF testing but with the convenience and affordability of a simple blood test.

The potential impact of integrating such a diagnostic reagent into widely used platforms like the Roche Elecsys®. This move could revolutionize Alzheimer's disease research, speeding up the evaluation of interventions and improving patient care.

With Alzheimer's disease and related dementias expected to affect millions globally, the necessity for faster, affordable, and reliable testing is paramount.

ALZpath aims to democratize access to its proprietary pTau217 antibody, forging partnerships with diagnostic leaders to make its technology available worldwide.

The impact on research, clinical trials, and patient care. The collaboration between ALZpath's antibody expertise and Roche's diagnostic instruments marks a significant step towards global access to testing as treatments evolve.








Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO Summit - USAHealthcare CMO Summit - USAHealthcare CFO, Financial Strategy & Revenue Cycle SummitHealthcare CEO & Executive Strategy Summit